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Background: Pulmonary tumour thrombotic microangiopathy (PTTM) is a rare complication of metastatic cancer
with a distinct histological appearance which presents with dyspnoea and pulmonary arterial hypertension and
leads to death in hours to days. It is a challenging diagnosis to make ante mortem, in part due to the rapid clinical
decline. Herein, we report a case of a young woman initially felt to have pulmonary sarcoidosis but who then died
eight days later from what was found at post mortem to be PTTM.
Case presentation: A 41 year old Caucasian woman presented with progressive dyspnoea. Computed tomography of
her thorax showed diffuse tiny centrilobular nodules in a tree-in-bud appearance along with small volume mediastinal
lymphadenopathy. A presumptive diagnosis of pulmonary sarcoidosis was made; bronchoscopy with transbronchial
lung biopsy was arranged to confirm the diagnosis. However, she rapidly deteriorated and died eight days later. Post
mortem examination revealed metastatic poorly differentiated gastric adenocarcinoma with PTTM being the final cause
of death.
Conclusion: This case demonstrates the diagnostic difficulties in such a rare and rapidly fatal oncological complication;
a greater awareness amongst clinicians may help make a positive diagnosis in the short window of time available. Little
is known about its pathogenesis, and even less about optimal management strategies. We review the literature to
demonstrate the clinical characteristics that might provide clues towards an ante mortem diagnosis, and highlight how
imatinib may provide the key to treating PTTM.
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Progressive dyspnoeaBackground
Pulmonary tumour thrombotic microangiopathy (PTTM)
is a rare complication of cancer with a prevalence of 1.4 %
in one retrospective autopsy series of patients who died of
cancer [1]. Clinically, it is characterised by dyspnoea and
pulmonary arterial hypertension, which almost invariably
progresses to right heart strain and cardiorespiratory arrest
in hours to days. Pathologically, there are widespread small
tumour emboli; it is distinct from conventional tumour
emboli in that there is fibrocellular intimal proliferation.* Correspondence: andrewlkho@doctors.org.uk
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often of diffuse centrilobular nodular opacities, for which
the differential diagnosis is wide.
Herein, we report a case of a young woman who pre-
sented with dyspnoea and was initially felt to have pul-
monary sarcoidosis. However, she rapidly deteriorated
and died eight days later. This case report serves to
highlight the diagnostic challenges involved in making a
timely diagnosis of PTTM, and reviews the possible
management options in this rare illness.s is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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A 41 year old Caucasian woman who was normally very
active presented with progressive dyspnoea over the
previous five months with an exercise tolerance deteri-
orating to twenty yards. She was a never-smoker and
her past medical history only mentioned spinal fusion
surgery in her thirties for congenital spinal scoliosis.
Her only medication was Microgynon (a combined oral
contraceptive pill). She denied any cough and was
otherwise systemically well. A short course of oral ste-
roids from her GP had temporarily improved her symp-
toms. Clinical examination was non-contributory; in
particular, her chest was clear to auscultation and there
was no peripherally palpable lymphadenopathy.
Postero-anterior chest radiograph was unremarkable.
Computed tomography pulmonary angiography (CTPA)
was performed on suspicion of pulmonary embolism
and she was given a single therapeutic dose of dalte-
parin. This demonstrated adequate opacification of the
pulmonary arterial tree with no evidence of filling
defect. There were diffuse tiny centrilobular soft tissue
nodules forming a tree-in-bud appearance with their
adjacent vessels, as well as small volume enlarged
lymph nodes in the mediastinum (measuring 11 mm in
short axis diameter at the left hilum and adjacent to theFig. 1 Axial slice of CTPA performed during the patient’s first
admission. CTPA demonstrated small centrilobular soft tissue
nodules with branching linear opacities forming a tree-in-bud
appearance. This is most often caused by obstruction of small
airways by, for example, mucus. In PTTM, however, it is caused by
tumour cells in distal arterioles and the resultant inflammation that
follows. The differential diagnosis for pulmonary nodular infiltrates
with mediastinal lymphadenopathy, particularly the small volume
adenopathy seen in our patient, is wide-ranging. It includes both
malignant causes such as lymphoma as well as benign causes such
as tuberculosis, inflammatory nodules, and sarcoidosisaortic arch) (Fig. 1). The combination of lymphadenop-
athy and nodular infiltrates especially along the fissures
and peripherally, in conjunction with the clinical pres-
entation, led to a provisional diagnosis of sarcoidosis,
although it was noted at the time that the differential
diagnosis for this radiological picture is far wider.
An electrocardiogram showed fixed T wave inversion
in leads III, aVF and V1. Transthoracic echocardiog-
raphy showed a mildly dilated right ventricle (RV) with
paradoxical motion of the RV septum indicating RV
overload (although the estimated pulmonary artery
pressures were not significantly elevated). Spirometry
showed a normal FEV1 and FVC with an FEV1/FVC
ratio of 73.4 %; lung volumes and transfer factors were
normal (table 1). Adjusted calcium was within the nor-
mal range; serum angiotensin-converting enzyme levels
were requested (later reported as normal at 26 IU/l).
She was discharged two days later with an appointment
for an outpatient bronchoscopy with transbronchial
lung biopsy.
She re-presented three days later feeling generally
unwell with worsening dyspnoea, nausea, loss of appe-
tite and diffuse headache. She was now tachycardic
(100 bpm), tachypnoeic (24/min) and hypoxic (SpO2
93 % on air). Clinical examination was once again non-
contributory. Arterial blood gas analysis showed type 1
respiratory failure (PaO2 8.18 kPa with FiO2 21 %).
Electrocardiography showed progression of the right
ventricular strain pattern with T wave inversion now in
leads III, aVF, and V1–4.
She was noted to have an isolated thrombocytopaenia
(93 x109/L); there was no clinical or laboratory evidence
of a hypercoagulable state. She was supported with oxy-
gen (up to 4 L/min via nasal cannulae) and also started
on co-amoxiclav and clarithromycin as she had a mild
neutrophilia (13.17 x109/L with C-reactive protein (CRP)
73 mg/l) to cover for an infective cause for her deterior-
ation. Bronchoscopy with transbronchial lung biopsy,
previously intended to be an outpatient investigation,Table 1 Pulmonary function tests
Spirometry
FEV1 2.47 L (80 % predicted)
FVC 3.37 L (94 % predicted)
FEV1/FVC 73.44 %
Transfer factors
TLCO 70 % predicted
KCO 85 % predicted
Body plethysmography
TLC 5.24 L (97 % predicted)
VC 3.39 L (93 % predicted)
Pulmonary function tests performed seven days ante mortem, including lung
volumes and transfer factors, were unremarkable
Fig. 3 Histological findings of pulmonary vasculature at post
mortem. Post mortem examination of the sections taken from both
lungs revealed widespread tumour emboli in small and medium sized
arterial vessels including sub-segmental branches of the pulmonary
arterial tree. This finding was associated with florid intimal fibrocellular
proliferation and muscular hyperplasia of the pulmonary vasculature
leading to luminal narrowing and stenosis with extensive intra-luminal
thrombosis. The pathological conclusion of PTTM is substantiated by
the clinical history of the patient's presentation and clinical outcome of
the case
Ho et al. BMC Cancer  (2015) 15:450 Page 3 of 5was organised as an inpatient to confirm the diagnosis
of pulmonary sarcoidosis. Corticosteroid therapy was
not initiated in order to maximise the diagnostic yield of
lung biopsy.
Two days after her readmission, whilst awaiting bron-
choscopy, she developed persistent tachycardia (100–
130 bpm) and tachypnoea (22–30/min) but with normal
blood pressure and stable peripheral oxygen saturations
on 2–4 L/min oxygen. She was noted to have an episode
of unresponsiveness similar to an absence seizure lasting
twenty seconds, followed by around thirty seconds of ab-
normal posturing (flexion but no jerking of limbs) and
urinary incontinence. Magnetic resonance imaging of her
head was performed to exclude neurosarcoidosis; this was
normal. Later the following day, eight days since her first
presentation, she suddenly deteriorated over a few minutes
and went into cardio-respiratory arrest with pulseless elec-
trical activity (PEA)/asystole. Despite a prolonged resusci-
tation attempt she passed away.
Post mortem examination revealed widespread tumour
emboli with associated thromboemboli in the subsegmental
branches of the pulmonary arterial tree; microscopically, the
appearances were consistent with a diagnosis of pulmonary
tumour thrombotic microangiopathy. The antecedent cause
for this was poorly differentiated adenocarcinoma with sig-
net ring cells in the anterior wall of the stomach (Figs. 2 and
3). Miliary metastases were found in the lung parenchyma
as well as metastatic deposits in the kidneys and bone mar-
row. Sections taken from the brain showed no evidence of
occlusive thrombosis or thromboemboli within the intracra-
nial blood vessels; the cause for the neurological event which
the patient experienced remains unknown. Retrospective
review of the history did not reveal any symptoms indicative
of dyspepsia, gastric malignancy, or (other than several
weeks of general malaise) occult malignant disease.Fig. 2 Histological findings of the stomach wall at post mortem.
Haematoxylin and eosin (H&E)-stained sections of the anterior
gastric wall showed adenocarcinoma with signet ring cell formsDiscussion
PTTM is a rare clinico-pathological entity first described
by von Herbay et al. in 1990. It is a complication of can-
cer characterised by widespread microscopic (usually
non-occlusive) tumour emboli in the pulmonary arteri-
oles. The distinction from conventional tumour emboli
is that it features localised activation of coagulation
pathways and the resultant histopathological finding of
fibrocellular intimal proliferation with or without sec-
ondary thrombosis [2, 3].
For reasons that are not known, the clear majority of
cases of PTTM arise from gastric adenocarcinomas,
often those of the signet ring cell subtype. In reviewing
all cases published in PubMed-indexed journals, we
found that gastric cancer accounts for around 60 % of
cases, with the remainder comprising lung cancer (9 %),
cancer of unknown primary (6 %), breast cancer (3 %),
and a few rarely-reported tumour sites.
The clinical presentation is typically of acute dys-
pnoea. There is a very rapid clinical course, progressing
to death in a matter of hours to days. Echocardiog-
raphy, if performed in a timely fashion, may show fea-
tures of pulmonary hypertension and right heart strain
(with raised pulmonary arterial pressure on right heart
catheterisation) [4, 5]. The picture of rapidly progres-
sive dyspnoea often prompts the team managing the
patient to organise a CT scan of the thorax. If angiog-
raphy is performed at the same time, it is usually nega-
tive for acute pulmonary embolism [1]. Instead, there
are diffuse centrilobular nodular opacities in a tree-in-
Ho et al. BMC Cancer  (2015) 15:450 Page 4 of 5bud pattern throughout the lung fields, with the pos-
sible additional signs of acute cor pulmonale [6–8].
A number of proteins have been implicated as media-
tors in the development of PTTM. Vascular endothelial
growth factor [1, 9] and tissue factor [10] are expressed
more frequently in cancer cells leading to PTTM than
those with traditional tumour emboli. Platelet-derived
growth factor (PDGF) is also expressed more frequently
in PTTM-associated cancer cells [9], although the asso-
ciation may be more complex with PDGF overexpres-
sion also present in alveolar macrophages and PDGF
receptor expression in the proliferating fibromuscular
intimal cells [11]. Osteopontin has also been implicated
[12, 13]. However, demonstrating overexpression of
these factors falls short to construct a model for the
pathogenesis of PTTM which remains to be elucidated.
As in our case, PTTM may well occur in patients
hitherto unknown to be harbouring malignant disease.
The combination of acute dyspnoea as the initial presen-
tation for metastatic disease combined with a rapid
deterioration makes ante mortem diagnosis a significant
challenge [14]. Indeed, there are only ten case reports in
the literature where the diagnosis of PTTM was made
whilst the patient was still alive: five were diagnosed by
transbronchial lung biopsy [15–19], two by video-assisted
thoracoscopic surgery [20, 21], one by CT-guided biopsy
[22]; the final two were presumptive ante mortem diagno-
ses based on proven pulmonary hypertension and the
finding of tumour cells from wedged pulmonary artery
catheter aspiration [23, 24].
Early ante mortem diagnosis is, however, only the first
step towards successful treatment. To date, there are only
four case reports in the literature of patients who survived
beyond the initial acute phase. The first was in 2007 when
a patient with VATS biopsy-proven PTTM from gastric
adenocarcinoma was treated with dexamethasone, war-
farin, aspirin and fluoropyrimidine-based chemotherapy.
The patient's symptoms and radiographic findings re-
solved, and she was well at six month follow-up [20].
The remaining three cases all experienced significant im-
provement following the administration of imatinib along-
side other medications such as prostacyclin analogs and
endothelial receptor antagonists to manage their pulmon-
ary hypertension. These patients had improved pulmonary
hypertension but died of either progressive disease [18, 23]
or, in one case, influenza infection [24]. There are reports
of imatinib being useful in pulmonary arterial hypertension
in the non-PTTM setting [25], although its use is currently
confined to clinical trials due to the IMPRES study which
showed increased morbidity from adverse events despite an
improvement in haemodynamics [26]. That imatinib ap-
pears to alter the natural history of PTTM lends credence
to the theory that PDGF is involved in the pathophysiology.
Disappointingly, although PDGF levels fell followingimatinib therapy, Ogawa et al. did not actually find PDGF
expression in either tumour cells or intimal cells. They
hypothesised that this was because the biopsy specimen
was taken after administration of imatinib and subsequent
clinical improvement [18].
An earlier diagnosis (such as on her first hospital ad-
mission) is unlikely to have changed the prognosis in
this lady with widespread carcinoma, but it should be
remembered that definitive diagnosis is not purely an
academic pursuit in terminal conditions. There is evi-
dence to suggest that the act of providing information to
cancer patients can reduce anxiety [27]. Knowledge of
their illness is valuable in that it allows patients to con-
textualise life decisions [28, 29].
Conclusions
This case shows the challenges of diagnosing and managing
PTTM. This is particularly true for three reasons: the rela-
tively non-specific symptom of dyspnoea; the fact that the
patient often does not have a known malignancy; and the
rate of clinical decline leading almost inevitably to death.
Clinicians should be aware of this as a diagnostic entity,
aided by the radiographic findings outlined above as well as
the developement of rapidly progressive pulmonary arterial
hypertension. More research into the pathogenesis of this
condition is clearly required, but given the cases outlined
above it seems reasonable that a trial of imatinib should
form part of the treatment strategy.
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